|
Director
|
 |
|
| |
| |
|
Dr. S.K. Puri,
FNASc
|
|
|
|
Immediate Past Director
CSIR-Central Drug Research Institute
Lucknow, 226 031
Uttar Pradesh
India |
|
|
|
| |
|
| |
| |
|
|
| Date of Birth:
23 November 1954 |
| |
| ACADEMIC
RECORD |
|
| |
|
| Degree |
Subject |
University |
Year |
| Ph.D. |
Thesis Title: Studies on Chemotherapy and Drug Resistance in Malaria |
CDRI, Lucknow / Panjab University, Chandigarh |
1979 |
| M.Sc. |
Zoology |
Panjab University, Chandigarh |
1976 |
| B.Sc. |
Zoology, Botany, Chemistry |
Panjab University, Chandigarh |
1974 |
|
| |
| Post
Division |
Organization |
Period |
| Chief Scientist (G) Div.
of Parasitology |
CSIR-Central Drug Research Institute, Lucknow |
Sept. 2004 - till date |
| Senior Principal Scientist (F) Div.
of Parasitology |
CSIR-Central Drug Research Institute, Lucknow |
Sept. 1999 - Sept.2004 |
| Principal Scientist (EII) Div.
of Microbiology |
CSIR-Central Drug Research Institute, Lucknow |
Sept. 1994-Sept.1999 |
| Senior Scientist (EI) Div.
of Microbiology |
CSIR-Central Drug Research Institute, Lucknow |
Sept. 1989-Sept.1994 |
| Scientist (C)
Div.
of Microbiology |
CSIR-Central Drug Research Institute, Lucknow |
Sept. 1986-Sept.1989 |
| Junior Scientist (B)
Div.
of Microbiology |
CSIR-Central Drug Research Institute, Lucknow |
Dec. 1982 -Sept.1986 |
|
| |
| |
| |
|
CURRENT AREA OF RESEARCH |
Dr S K Puri’s major scientific contributions have been directed towards Preclinical discovery & development of novel fast acting blood schizontocidal antimalarials,
safe and effective antimalarials for anti-relapse, gametocytocidal and prophylactic use; and establishment of new in vitro / in vivo models. Infectious diseases are a
cause of major concern to human health in developing countries. Among the parasitic diseases malaria is acknowledged as the most dreaded disease and features as one of the
top priorities in our National health programme. His contributions in development of new trioxane compounds as synthetic substitutes to artemisinine derivatives would provide
cost effective therapeutic interventions for treatment of cases due to drug resistant Plasmodium falciparum which constitutes about 40% of the annual malaria incidence.
Plasmodium vivax is the other major human malaria parasite responsible for 60% malaria incidence. Development of new anti-relapse antimalarial drugs have provided safer
substitutes to primaquine for treatment of relapses in P. vivax patients. Development of cost-effective antimalarial drugs is directed to reduce the burden of malaria in
disease endemic areas.
|
|
|
| PUBLICATIONS
|
213 |
|
|
| |
| HONOURS &
AWARDS |
|
| Honour &
Award |
Conferred by |
| Fellowship of National Academy of Sciences
(FNASc) in 2009 |
The National academy of Sciences, (NASI) Allahabad |
| CSIR Technology award for Innovation
in 2009. To “ Team CDRI” for
‘Development of Synthetic Endoperoxide Antimalarials as substitute to Artemisinine Derivatives’. |
Council of Scientific and Industrial Research, (CSIR) New Delhi |
| Dr BN Singh Memorial Oration award
in 2005. |
The Indian society for Parasitology (ISP) |
|
|
|
|
| |
LIST OF RESEARCH
PUBLICATIONS |
| |
|
|
|
|
| |
| |
|
| |
|
